NCT05162183View on ClinicalTrials.gov

Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

3,474

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Diabetes
Interventions
DRUG

Glimepiride

Glimepiride dispensing claim is used as the reference group.

DRUG

Liraglutide

Liraglutide dispensing claim is used as the exposure group.

Trial Locations (1)

02135

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT05162183 - Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter